USFDA 483 / Intas / May 2023 /Failure to
USFDA 483 to Intas cites lapses in investigation and review of failures and discrepancies in
Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA 483 to Intas cites lapses in investigation and review of failures and discrepancies in
USFDA483 to Intas cites manipulated visual inspection reports; failure to characterise particles observed in injection
FDA published the USFDA483 issued to Intas site (FEI 3003157498) in Ahmedabad, India after inspection
USFDA Inspection at Cadila Ahmedabad, India in April-May 2019 by Investigators Justin A Boyd, Thomas
Aurobindo Unit 1 (FEI 3004021253) was inspected by USFDA investigator Rita K Kabaso from August
Aurobindo Unit 1 (FEI 3004021253) was inspected by USFDA investigator Rita K Kabaso from August